MannKind’s Afrezza Remains in Sanofi’s Plans, RBC Says

Yesterday, Sanofi hosted a seminar on new medicines in Cambridge, Mass., and RBC’s Adnan Butt and team note that MannKind’s (MNKD) inhaled insulin Afrezza “featured prominently enough.” They summarize the highlights of the presentation: Reuters MannKind’s partner reiterated prior guidance that a commercial launch is planned for 1Q:15. Some had feared this timing could be [...]